Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in … – Yahoo Finance
|
Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR–T Trial of Axicabtagene Ciloleucel in …
Yahoo Finance Kite Pharma, Inc., (KITE) today announced two plenary presentations of positive data from the primary analysis of ZUMA-1 for its lead CAR–T candidate, axicabtagene ciloleucel, in patients with refractory aggressive B-cell non-Hodgkin lymphoma (NHL) at … |
